Last reviewed · How we verify
Adjuvant treatment
Adjuvant treatment is a Immune checkpoint inhibitor Small molecule drug developed by GERCOR - Multidisciplinary Oncology Cooperative Group. It is currently in Phase 2 development for Adjuvant treatment of melanoma. Also known as: cisplatin / cisplatinum, etoposide / vepesid, carbopatin / paraplatin.
This drug works by enhancing the body's immune response to cancer.
This drug works by enhancing the body's immune response to cancer. Used for Adjuvant treatment of melanoma.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 2 attrition
-2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Adjuvant treatment |
|---|---|
| Also known as | cisplatin / cisplatinum, etoposide / vepesid, carbopatin / paraplatin |
| Sponsor | GERCOR - Multidisciplinary Oncology Cooperative Group |
| Drug class | Immune checkpoint inhibitor |
| Target | CD137 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Adjuvant treatment drugs like this one are designed to stimulate the immune system to recognize and attack cancer cells. They typically work by activating immune cells, such as T cells, to target and destroy cancer cells.
Approved indications
- Adjuvant treatment of melanoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Rash
- Pruritus
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer (PHASE2)
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma (PHASE2)
- Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2) (PHASE2)
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adjuvant treatment CI brief — competitive landscape report
- Adjuvant treatment updates RSS · CI watch RSS
- GERCOR - Multidisciplinary Oncology Cooperative Group portfolio CI
Frequently asked questions about Adjuvant treatment
What is Adjuvant treatment?
How does Adjuvant treatment work?
What is Adjuvant treatment used for?
Who makes Adjuvant treatment?
Is Adjuvant treatment also known as anything else?
What drug class is Adjuvant treatment in?
What development phase is Adjuvant treatment in?
What are the side effects of Adjuvant treatment?
What does Adjuvant treatment target?
Related
- Drug class: All Immune checkpoint inhibitor drugs
- Target: All drugs targeting CD137
- Manufacturer: GERCOR - Multidisciplinary Oncology Cooperative Group — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Adjuvant treatment of melanoma
- Also known as: cisplatin / cisplatinum, etoposide / vepesid, carbopatin / paraplatin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing